Sandra Calvin, SVP, Chief Accounting Officer: Travere Therapeutics TVTX Sell · Filed 25/01/23

Trade details

Type: Insider sale
Amount: $17,519.5
Shares · price: 925 sh · $18.94 a share
Held after: 54,002 sh
Stock: Travere Therapeutics TVTX
Person: Sandra CalvinSVP, Chief Accounting Officer
Trade date: 25/01/22
Filed: 25/01/23
Days to filing: 1 days

Sold 1.7% of holdings

Share of holding sold: 1.7%

Travere Therapeutics trades, last 26 weeks

What else happened in Travere Therapeutics around then

Filed or reported within 30 days of the trade day · 24/12/23~25/02/21

Sandra Calvin's recent trades

Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$353.6K
5,375 sh
$353.6K
Filed 09/15
Traded 09/15
Sandra CalvinSVP, Chief Accounting Officer
Sell10b5-1 planTravere Therapeutics
Sell10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/16
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/14
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned saleTravere Therapeutics
Planned sale
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03
Sandra CalvinSVP, Chief Accounting Officer
SellTravere Therapeutics
Sell
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03